PCC AI Genomic Immune Factors - Stand Up To Cancer

Research Teams

Research  >  Research Portfolio  >  Research Teams  >  PCC AI Genomic Immune Factors

Pancreatic Cancer Collective Research Team: Computational Approaches To Identifying High-Risk Pancreatic Cancer Populations – Identification of Genomic and Immune Factors in High-Risk Populations for Pancreatic Cancer

Grant Term: May 2019 – April 2021

This interdisciplinary, multi‐institutional, and international team will focus on developing a collection of biomarkers that predict an individual’s risk of developing pancreatic cancer. Samples will be obtained from large clinical and molecular datasets, and the research will be complemented by the identification of tumor microenvironmental factors to create a screening tool for pancreatic cancer risk.


This team will develop a collection of biomarkers for pancreatic cancer which will be obtained from large clinical and molecular datasets with multiple cohorts. Specifically, they will look at rare gene variants, or modifications of the DNA, in specific regions which, when analyzed together, will predict an individual’s risk of developing pancreatic cancer. The datasets include the UK Biobank, European Study on Digestive Illnesses and Genetics, The Cancer Genome Atlas, and International Cancer Genome Consortium. This approach will be complemented with the examination of tumor microenvironmental factors which are associated with pancreatic cancer risk, including gene expression patterns and response to bacterial and viral infections. This is a high-risk, high-reward project that, if successful, will integrate clinical, genetic, and microenvironmental factors to revolutionize screening and risk-prediction for pancreatic cancer.

This team is part of the Pancreatic Cancer Collective, an initiative of Lustgarten Foundation for Pancreatic Cancer Research and Stand Up To Cancer.


Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.